🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

58 results for “dexmedetomidine” Clear

  1. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  2. Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion, Midazolam Lek 1 mg/ml raztopina za injiciranje/infundiranje

    Tour Hekla

    Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:

    phase 3 small molecule active

    1 trial

  3. MIDAZOLAM, DEXMEDETOMIDINE EVER PHARMA 100 microgrammes/mL, solution à diluer pour perfusion

    Pari Pharma GmbH

    Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  4. SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Children under the age of 2 years having surgery lasting at least 2 hours

    phase 3 small molecule active

    1 trial

  5. Sublingual film containing Dexmedetomidine (BXCL501)

    BioXcel Therapeutics

    Agitation Associated With Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  6. Sublingual film containing dexmedetomidine (BXCL501)

    BioXcel Therapeutics

    Agitation

    phase 3 small molecule completed

    1 trial

  7. Caudal Dexmedetomidine

    China SXT Pharmaceuticals

    Inguinal Hernia

    phase 2 small molecule completed

    1 trial

  8. Dexmedetomidine

    BioXcel Therapeutics

    Opioid Withdrawal

    phase 2 small molecule completed

    1 trial

  9. Dexmedetomidine

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  10. Dexmedetomidine injection

    Sana Biotechnology

    Post Spinal Shivering

    phase 2 small molecule active

    1 trial

  11. Dexmedetomidine sublingual film

    BioXcel Therapeutics

    Delirium

    phase 2 small molecule terminated

    1 trial

  12. Sublingual film containing Dexmedetomidine

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 2 small molecule completed

    1 trial

  13. Dexmedetomidine

    First Tracks Biotherapeutics

    Cesarean Section, Affecting Fetus or Newborn

    phase 1 small molecule completed

    1 trial

  14. Dexmedetomidine

    First Tracks Biotherapeutics

    Heart Injuries

    phase 1 small molecule active

    1 trial

  15. Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg

    BioXcel Therapeutics

    Alcohol Use Disorder (AUD)

    phase 1 small molecule active

    1 trial

  16. Sublingual film containing BXCL501 (Dexmedetomidine)

    BioXcel Therapeutics

    Agitation

    phase 1 small molecule completed

    1 trial

  17. 0.3% ropivacaine and 50 μg dexmedetomidine

    China SXT Pharmaceuticals

    Free Flap Reconstruction

    approved small molecule active

    1 trial

  18. Dexmedetomidine

    First Tracks Biotherapeutics

    Elderly

    approved small molecule completed

    3 trials

  19. Dexmedetomidine

    First Tracks Biotherapeutics

    Overall Survival

    approved small molecule completed

    1 trial

  20. Dexmedetomidine

    First Tracks Biotherapeutics

    Older Patients

    approved small molecule active

    1 trial

  21. Dexmedetomidine

    First Tracks Biotherapeutics

    Breast Cancer

    approved small molecule completed

    1 trial

  22. Dexmedetomidine

    First Tracks Biotherapeutics

    Obstructive Sleep Apnea

    approved small molecule completed

    1 trial

  23. Dexmedetomidine

    First Tracks Biotherapeutics

    Renal Function

    approved small molecule active

    1 trial

  24. Dexmedetomidine

    United Therapeutics Europe Ltd

    Breast Cancer

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources